Nanjing Leads Biolabs Showcases Next-Generation Cancer ADCs at 2026 AACR Meeting

An announcement from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.

Nanjing Leads Biolabs announced that two of its preclinical oncology programs have been accepted for presentation at the 2026 American Association for Cancer Research Annual Meeting in San Diego. The featured assets, LBL-054 TDC and LBL-061, are designed to provide highly targeted, lower-toxicity treatment options for a range of solid tumors by combining antibody-drug conjugate mechanisms with immune activation.

LBL-054 TDC, a first-in-class CDH17-targeted T cell engager drug conjugate for gastrointestinal cancers, showed strong anti-tumor efficacy in preclinical models, with potent cytotoxicity against tumor cells, limited impact on T cells, and favorable tolerability in primate studies. LBL-061, an EGFR/PD-L1 bispecific ADC aimed at multiple solid tumors, demonstrated robust tumor cell killing, immune pathway blockade, and durable tumor growth inhibition in animal models, alongside acceptable safety margins in dose-ranging studies, underscoring the company’s growing presence in next-generation cancer therapeutics.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative oncology therapies. Its research centers on T cell engager-drug conjugates and bispecific antibody-drug conjugates, leveraging three proprietary platforms—LeadsBody, X-body, and TOPiKinetics—to target solid tumors such as gastrointestinal, lung, and head and neck cancers.

Average Trading Volume: 618,456

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$14.82B

Find detailed analytics on 9887 stock on TipRanks’ Stock Analysis page.